Brief: Liminatus Pharma Announces Planned Phase 1 Clinical Trial Of Iba101, A Next-Generation Cd47 Blocking Antibody
17/03/2026 12:09
March 17 (Reuters) - Liminatus Pharma Inc LIMN.O: LIMINATUS PHARMA ANNOUNCES PLANNED PHASE 1 CLINICAL TRIAL OF IBA101, A NEXT-GENERATION CD47 BLOCKING ANTIBODY Source text: ID:nGNX1hPNcj Further company coverage: LIMN.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Liminatus Pharma
See all newsNASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Liminatus Pharma Announces Reverse Stock Split Of Its Common Stock
Brief: Liminatus Pharma Announces Planned Phase 1 Clinical Trial Of Iba101, A Next-Generation Cd47 Blocking Antibody
Brief: Liminatus Pharma Enters Settlement Agreement With Clear Street LLC